DexCom earnings beat by $0.03, revenue topped estimates
WALTHAM, Mass. - Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS), a robotics technology firm focused on the development of surgical robots, announced today that its Chief Operating Officer, John Mazzola, is set to retire on April 1, 2025, after a career spanning nearly four decades in the healthcare sector. Mazzola will maintain his role until his retirement, at which point his duties will be assumed by Randy Clark, the company’s current President. The announcement comes as the company’s stock has shown strong momentum, with a 157% price return over the past six months.
During his tenure, Mazzola has played a pivotal role in refining corporate manufacturing processes, enhancing product quality control, and fortifying the company’s supply chain, according to Adam Sachs, Co-Founder and CEO of Vicarious Surgical. "We are deeply grateful for his contributions and wish him a happy and fulfilling retirement," Sachs expressed.
Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is pioneering a novel surgical approach with its proprietary human-like surgical robots. These robots are designed to virtually transport surgeons inside the patient to perform minimally invasive surgery. The company is preparing for its first clinical use cases and a pivotal trial of its innovative technology. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.44, though it is currently experiencing rapid cash burn. For deeper insights, InvestingPro offers 10+ additional exclusive tips about RBOT’s financial health and market position.
The company’s leadership team includes an array of technologists, medical device professionals, and physicians. Vicarious Surgical has garnered support from notable investors such as Bill Gates, Khosla Ventures, Innovation Endeavors, AME Cloud Ventures, Sun Hung Kai & Co. Ltd, and E15 VC.
This press release contains forward-looking statements regarding the company’s future operations and product development. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that may influence these outcomes include market conditions, regulatory approvals, competition, and the company’s ability to secure additional financing and maintain its NYSE listing, among others. Based on InvestingPro’s Fair Value analysis, the stock appears to be currently trading near its fair value. Investors seeking comprehensive analysis can access the detailed Pro Research Report, available for RBOT and 1,400+ other US stocks, offering expert insights and actionable intelligence for informed decision-making.
The information in this article is based on a press release statement from Vicarious Surgical Inc.
In other recent news, Vicarious Surgical Inc. has entered into a consulting agreement with its former Chief Financial Officer, William Kelly, following his departure from an executive role. Effective from January 17, 2025, Mr. Kelly will offer advisory services to the company until December 31, 2028. His compensation will initially be a monthly rate of $10,000 for the first six months, transitioning to an hourly rate from July 1, 2025. Kelly will maintain the vesting rights to his stock options and restricted stock units granted under Vicarious Surgical’s 2021 Equity Incentive Plan until June 30, 2025. The agreement includes standard clauses for confidentiality and non-solicitation, ensuring Kelly’s continued commitment to the company. These are recent developments as Vicarious Surgical continues to evolve strategically in the medical device sector. Further details of the agreement will be disclosed in the company’s upcoming Annual Report on Form 10-K for the fiscal year ending December 31, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.